[go: up one dir, main page]

EA200201017A1 - Кристаллическая форма ii каберголина - Google Patents

Кристаллическая форма ii каберголина

Info

Publication number
EA200201017A1
EA200201017A1 EA200201017A EA200201017A EA200201017A1 EA 200201017 A1 EA200201017 A1 EA 200201017A1 EA 200201017 A EA200201017 A EA 200201017A EA 200201017 A EA200201017 A EA 200201017A EA 200201017 A1 EA200201017 A1 EA 200201017A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cabergoline
cabergolina
crystal form
solvent
suspending
Prior art date
Application number
EA200201017A
Other languages
English (en)
Other versions
EA004376B1 (ru
Inventor
Аттилио Томази
Стефания Мадженес
Джулиано Рамелла
Марио Унгари
Марко Пандольфи
Original Assignee
Фармация Италия С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Италия С.П.А. filed Critical Фармация Италия С.П.А.
Publication of EA200201017A1 publication Critical patent/EA200201017A1/ru
Publication of EA004376B1 publication Critical patent/EA004376B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение раскрывает кристаллическую форму II каберголина, содержащую ее фармацевтическую композицию и способ её получения. Способ может включать кристаллизацию из раствора сырого каберголина в органическом растворителе при низких температурах или суспендирование смеси каберголина форм I и II в растворителе при температуре ниже приблизительно 30°С.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200201017A 2000-03-24 2001-03-19 Кристаллическая форма ii каберголина EA004376B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007307.2A GB0007307D0 (en) 2000-03-24 2000-03-24 Crystalline form || of cabergoline
PCT/EP2001/003098 WO2001072747A1 (en) 2000-03-24 2001-03-19 Crystalline form ii of cabergoline

Publications (2)

Publication Number Publication Date
EA200201017A1 true EA200201017A1 (ru) 2003-02-27
EA004376B1 EA004376B1 (ru) 2004-04-29

Family

ID=9888432

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201017A EA004376B1 (ru) 2000-03-24 2001-03-19 Кристаллическая форма ii каберголина

Country Status (31)

Country Link
US (2) US6673806B2 (ru)
EP (1) EP1280803B1 (ru)
JP (1) JP2003528874A (ru)
KR (1) KR20020081492A (ru)
CN (1) CN1221550C (ru)
AR (1) AR048279A1 (ru)
AT (1) ATE282038T1 (ru)
AU (1) AU783064B2 (ru)
BR (1) BR0109508A (ru)
CA (1) CA2399540A1 (ru)
CZ (1) CZ20023177A3 (ru)
DE (1) DE60107074T2 (ru)
DK (1) DK1280803T3 (ru)
EA (1) EA004376B1 (ru)
EE (1) EE200200544A (ru)
ES (1) ES2231461T3 (ru)
GB (1) GB0007307D0 (ru)
HK (1) HK1052692B (ru)
HU (1) HUP0300389A3 (ru)
IL (1) IL151670A0 (ru)
MX (1) MXPA02009284A (ru)
MY (1) MY126071A (ru)
NO (1) NO20024527D0 (ru)
NZ (1) NZ521314A (ru)
PE (1) PE20011087A1 (ru)
PL (1) PL358252A1 (ru)
PT (1) PT1280803E (ru)
SI (1) SI1280803T1 (ru)
SK (1) SK13572002A3 (ru)
WO (1) WO2001072747A1 (ru)
ZA (1) ZA200207151B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
KR100622512B1 (ko) * 2002-03-15 2006-09-13 파마시아 코포레이션 카베르골린의 결정형 ι의 제조 방법
IL155545A (en) * 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
US7531551B2 (en) * 2003-05-08 2009-05-12 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1953157A1 (en) * 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US20130163062A1 (en) 2011-12-22 2013-06-27 Qualcomm Mems Technologies, Inc. Mechanical smart window with continuously tunable transmission

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US149067A (en) * 1874-03-31 Improvement in steam-engine valve-gears
US187013A (en) * 1877-02-06 Improvement in ovens for gas-stoves
US144516A (en) * 1873-11-11 Improvement in faucets
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007376D0 (en) 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
CN1418213A (zh) 2003-05-14
PE20011087A1 (es) 2001-10-04
MXPA02009284A (es) 2003-03-12
EP1280803B1 (en) 2004-11-10
US6800635B2 (en) 2004-10-05
DE60107074D1 (de) 2004-12-16
KR20020081492A (ko) 2002-10-26
NO20024527L (no) 2002-09-20
ES2231461T3 (es) 2005-05-16
BR0109508A (pt) 2002-12-17
ATE282038T1 (de) 2004-11-15
NZ521314A (en) 2004-05-28
HK1052692B (zh) 2006-03-03
PL358252A1 (en) 2004-08-09
HUP0300389A3 (en) 2004-08-30
US20040072855A1 (en) 2004-04-15
ZA200207151B (en) 2003-09-05
CN1221550C (zh) 2005-10-05
SK13572002A3 (sk) 2003-04-01
DE60107074T2 (de) 2005-10-20
EA004376B1 (ru) 2004-04-29
WO2001072747A1 (en) 2001-10-04
EP1280803A1 (en) 2003-02-05
CZ20023177A3 (cs) 2003-03-12
EE200200544A (et) 2004-04-15
MY126071A (en) 2006-09-29
AU4248201A (en) 2001-10-08
GB0007307D0 (en) 2000-05-17
AU783064B2 (en) 2005-09-22
CA2399540A1 (en) 2001-10-04
NO20024527D0 (no) 2002-09-20
US20030187013A1 (en) 2003-10-02
SI1280803T1 (en) 2005-04-30
US6673806B2 (en) 2004-01-06
AR048279A1 (es) 2006-04-19
DK1280803T3 (da) 2005-01-24
IL151670A0 (en) 2003-04-10
PT1280803E (pt) 2005-02-28
JP2003528874A (ja) 2003-09-30
HK1052692A1 (en) 2003-09-26
HUP0300389A2 (hu) 2003-07-28

Similar Documents

Publication Publication Date Title
EA200201017A1 (ru) Кристаллическая форма ii каберголина
AR021380A1 (es) COMPUESTOS DIPEPTIDOS CON ELEVADA ACTIVIDAD FUNGUICIDA, SU EMPLEO EN AGRONOMIA, COMPOSICIONES FUNGUICIDAS QUE CONTIENEN A DICHOS COMPUESTOS, PROCEDIMIENTO PARA LA PREPARACIoN DE DICHAS COMPOSICIONES Y MÉTODO PARA COMBATIR INFECCIONES DE HONGOS EMPLEANDO EL COMPUESTO DIPÉPTIDO.
EA199900083A1 (ru) Замещенные пиридо- или пиримидосодержащие 6,6 или 6,7-бициклические производные
AR042486A1 (es) Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
EA200300103A1 (ru) НОВАЯ β КРИСТАЛЛИЧЕСКАЯ ФОРМА ТРЕТ-БУТИЛАМИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
PE20010613A1 (es) Antagonistas de la hormona concentradora de la melanina
BR1100375A (pt) Composto, composição farmacêutica, e, processo para a preparação de um composto
EA200400491A1 (ru) Полиморфная форма римонабанта, способ её получения и содержащие её фармацевтические композиции
EA200600594A1 (ru) Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
EA200001221A1 (ru) Новая форма ирбесартана, способы получения указанной формы и содержащие ее фармацевтические композиции
EA199900720A1 (ru) Способ кристаллизации ингибитора обратной транскриптазы с применением противорастворителя
MX9602979A (es) Compuestos heterociclicos terapeuticos.
DK1399436T3 (da) Oxytocinagonister
BR9809652A (pt) Derivados de quinolina-4-carboxamida como antagonistas de receptor nk-2 e nk-3
EA200101234A1 (ru) Новые производные аминотиазола, их получение и содержащие их фармацевтические композиции
WO2003016316A8 (en) Diazacycloalkanes as oxytocin agonists
DK0628042T3 (da) Serotoninerge ergolinderivater
Łukasik et al. A new approach to the synthesis of 1-arylbenzimidazole-2-thiones from nitroarenes and anilines through halogen-free substitution of hydrogen via iminophosphorane intermediates
DK1102765T3 (da) Fremgangsmåde til syntese af (1H)-benzo[c]quinolizin-3-on-derivater
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
BR0211670A (pt) Processos para a produção de compostos e compostos
AR026222A1 (es) Compuestos derivados de acido antranilico
FI915875L (fi) Menetelmä yleisen kaavan I mukaisten lääkeaineina käyttökelpoisten 2,3-dihydro-4H-1,3-bentsoksatsinon-4-onien ja 2,3-dihydro-4H-bentsotiatsinon-4-onien nitro-oksijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU